SCHEMBL1245129

SCHEMBL1245129

COc1cc(C(=O)Cc2ccc(O)cc2)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.58
SLC22A6 Q4U2R8 1/20 0.58
SLC22A8 Q8TCC7 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
HTT P42858 2/20 0.57
PTPN7 P35236 1/20 0.57
DUSP3 P51452 1/20 0.57
NFKB1 P19838 2/20 0.56
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
TSHR P16473 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
HSD17B2 P37059 1/20 0.54
CYP1A2 P05177 1/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
BLM P54132 1/20 0.52
MAOB P27338 1/20 0.51
NPC1 O15118 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28447398 0.91 GAA (0.69) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL6060544 0.88 HTT (0.61) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL30504089 0.84 SLC22A6 (0.57) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL2049829 0.82 KMT2A (0.55) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL15540877 0.81 GAA (0.69) MEN1KMT2ANFKB1ALDH1A1GAA
SCHEMBL28524422 0.81 PTPN7 (0.53) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL30504071 0.81 GAA (0.63) RAB9ASLC22A6SLC22A8MEN1KMT2A
SCHEMBL4475231 0.80 NPC1 (0.56) RAB9AMEN1KMT2AHTTALDH1A1
SCHEMBL597343 0.79 ALOX5 (0.65) SLC22A6SLC22A8MEN1KMT2ANFKB1
SCHEMBL30358985 0.79 ALOX5 (0.65) SLC22A6SLC22A8MEN1KMT2ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386211-B1 USE OF RUBUSOSIDE TO REDUCE OR SUPPRESS PARTICULAR UNPLEASANT TASTE SENSATIONS SYMRISE AG (DE) 2016-08-10 EP claimed
EP-2386211-A1 Use of rubusoside to reduce or suppress particular unpleasant taste sensations Symrise AG (DE) 2011-11-16 EP claimed
US-8041053-B2 Vehicular sound effect generating apparatus HONDA MOTOR CO., LTD. (JP) 2011-10-18 US claimed
US-10165791-B2 Use of rubusoside for reducing or suppressing certain unpleasant taste impressions SYMRISE AG (DE) 2019-01-01 US disclosed
US-20180070620-A1 USE OF RUBUSOSIDE FOR REDUCING OR SUPPRESSING CERTAIN UNPLEASANT TASTE IMPRESSIONS SYMRISE AG (DE) 2018-03-15 US disclosed
EP-2292224-B1 Derivatives of lactiosole for preventing or treating diabetes SYMRISE AG (DE) 2018-03-07 EP disclosed
US-9848624-B2 Use of rubusoside for reducing or suppressing certain unpleasant taste impressions SYMRISE AG (DE) 2017-12-26 US disclosed
EP-2386211-B1 USE OF RUBUSOSIDE TO REDUCE OR SUPPRESS PARTICULAR UNPLEASANT TASTE SENSATIONS SYMRISE AG (DE) 2016-08-10 EP disclosed
US-20140287122-A1 USE OF RUBUSOSIDE FOR REDUCING OR SUPPRESSING CERTAIN UNPLEASANT TASTE IMPRESSIONS SYMRISE AG (DE) 2014-09-25 US disclosed
US-8592621-B2 Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease SYMRISE AG (DE) 2013-11-26 US disclosed
EP-2386211-A1 Use of rubusoside to reduce or suppress particular unpleasant taste sensations Symrise AG (DE) 2011-11-16 EP disclosed
US-8041053-B2 Vehicular sound effect generating apparatus HONDA MOTOR CO., LTD. (JP) 2011-10-18 US disclosed
EP-2292224-A1 Precursor compounds of sweet receptor antagonists for preventing or treating diabetes Symrise AG (DE) 2011-03-09 EP disclosed
US-20110045069-A1 PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE SYMRISE GMBH CO. KG (DE) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110045069-A1 PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE TAS1R2, TAS2R5, TAS2R1 RAB9A 1633/4885SLC22A6 748/4885SLC22A8 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.